Custom Retatrutide CAS NO: 2381089-83-2 Quotes, Pricelist
Product Description
Mechanism & Efficacy
Retatrutide is a novel multi-agonist peptide targeting GLP-1, GIP, and glucagon receptors, designed to enhance glucose regulation, promote weight loss, and support metabolic health. It is under active investigation in clinical and preclinical research for obesity and type 2 diabetes management.
Dosage & Research Use
Retatrutide is currently an investigational peptide in Phase 3 clinical trials and not yet FDA‑approved for clinical use. Trial protocols have explored once‑weekly subcutaneous doses ranging from 1 mg up to 12 mg, often titrated over multiple 4‑week intervals to balance efficacy and tolerability.
Patents & Intellectual Property
Retatrutide’s patent landscape is evolving; as a novel triple‑agonist peptide, Eli Lilly holds patents on synthetic methods, compositions, and use cases. While precise global expirations vary, some core protections will likely extend well into the late 2020s and early 2030s, with additional exclusivity possible if classified as a biologic.
Because retatrutide is not yet FDA‑approved, its final patent protection timeline could shift upon regulatory submission and approval.
Quality & Compliance
Manufactured in state-of-the-art cGMP facilities, each batch undergoes rigorous testing for purity, stability, and identity to ensure research-grade quality.
Customer Service & Shipping
Our team provides professional consultation for experimental design and peptide handling. Products are shipped with customized temperature-controlled solutions to maintain integrity, with tracking provided for all orders.
Therapeutic Areas
This review synthesizes findings from preclinical and clinical studies, highlighting retatrutide’s mechanisms, efficacy, and safety profile. Retatrutide’s unique molecular structure enables potent activation of GLP-1, GIP, and glucagon receptors, leading to significant weight reduction, improved glycemic control, and favorable metabolic outcomes. Animal studies demonstrate retatrutide’s ability to delay gastric emptying, reduce food intake, and promote weight loss, with superior efficacy compared to other incretin-based therapies. Phase I and II clinical trials corroborate these findings, showing dose-dependent weight loss, reductions in Glycated Hemoglobin (HbA1c) levels, and improvements in liver steatosis and diabetic kidney disease. Common adverse effects are primarily gastrointestinal and dose-related. Ongoing Phase III trials, such as the TRIUMPH studies, aim to further evaluate retatrutide’s long-term safety and efficacy in diverse patient populations. While retatrutide shows immense promise, considerations regarding cost and the quality of weight loss beyond BMI reduction warrant further investigation. Retatrutide heralds a new era in obesity and T2DM treatment, offering hope for improved patient outcomes.
Outlook & Development
Treatment with retatrutide was associated with improvements in cardiometabolic measures (exploratory endpoints) including systolic and diastolic blood pressure, triglycerides, LDL-cholesterol, total cholesterol, HbA1c, and fasting glucose and insulin at weeks 24 and 48.
Retatrutide appears to herald a significant advancement in the realm of pharmacotherapy for obesity and weight management. With its remarkable safety profile and noteworthy percentages of weight reduction, it undeniably generates considerable enthusiasm within the medical community. However, it is essential to emphasize that additional phase 3 clinical trials are crucial to further evaluate the drug’s safety and long-term effects.
Retatrutide is a novel triple receptor agonist targeting GLP-1, GIP, and glucagon receptors. It is designed to enhance glucose regulation, promote significant weight loss, and support overall metabolic health in obesity and type 2 diabetes research.
No, Retatrutide is currently an investigational peptide undergoing Phase 3 clinical trials (such as the TRIUMPH studies) and has not yet received FDA approval for clinical use.
Clinical trial protocols explore once-weekly subcutaneous doses ranging from 1 mg up to 12 mg, titrated over 4-week intervals to optimize efficacy and tolerability.
Eli Lilly holds patents covering synthetic methods, compositions, and use cases for Retatrutide. Core patent protections are expected to extend into the late 2020s and early 2030s.
Retatrutide is manufactured in state-of-the-art cGMP facilities. Every batch is subjected to stringent testing for purity, stability, and identity to meet research-grade standards.
Studies show improvements in systolic/diastolic blood pressure, triglycerides, LDL-cholesterol, total cholesterol, HbA1c, as well as fasting glucose and insulin levels at 24 and 48 weeks.
